Jason Xu
Overview
Explore the profile of Jason Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Q, Boccalatte F, Xu J, Gambi G, Nadorp B, Akter F, et al.
J Exp Med
. 2025 Feb;
222(4).
PMID: 39969525
While the mutational landscape across early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and ETP-like leukemia is known, establishing a unified framework that activates stem cell genes characteristic of these tumors...
2.
Ding Y, Sussman J, Madden K, Loftus J, Chen R, Falkenstein C, et al.
Blood
. 2025 Jan;
145(11):1195-1210.
PMID: 39774844
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) is driven by genetic alterations that induce constitutive kinase signaling and is associated with chemoresistance and high relapse risk in children and...
3.
Xu J, Chen C, Sussman J, Yoshimura S, Vincent T, Polonen P, et al.
Nat Cancer
. 2024 Nov;
6(1):102-122.
PMID: 39587259
Refractoriness to initial chemotherapy and relapse after remission are the main obstacles to curing T cell acute lymphoblastic leukemia (T-ALL). While tumor heterogeneity has been implicated in treatment failure, the...
4.
Elghawy O, Cao M, Xu J, Landsburg D, Svoboda J, Nasta S, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410047
T-cell lymphomas (TCLs) are a group of heterogenous cancers with poor rates and duration of response. There remains a great challenge in risk stratification of these cancers. Cluster of differentiation...
5.
Xu J, Billimek J, Kim B
Fam Med
. 2024 Aug;
56(9):579-583.
PMID: 39207789
Background And Objectives: Musculoskeletal (MSK) complaints comprise more than 20% of all visits to health care providers each year. Despite required experiences in MSK care, family physicians report low confidence...
6.
Teachey D, Newman H, Lee S, Polonen P, Shraim R, Li Y, et al.
Res Sq
. 2024 Aug;
PMID: 39184069
The influence of genetic ancestry on biology, survival outcomes, and risk stratification in T-cell Acute Lymphoblastic Leukemia (T-ALL) has not been explored. Genetic ancestry was genomically-derived from DNA-based single nucleotide...
7.
Polonen P, Di Giacomo D, Seffernick A, Elsayed A, Kimura S, Benini F, et al.
Nature
. 2024 Aug;
632(8027):1082-1091.
PMID: 39143224
T-lineage acute lymphoblastic leukaemia (T-ALL) is a high-risk tumour that has eluded comprehensive genomic characterization, which is partly due to the high frequency of noncoding genomic alterations that result in...
8.
Bu F, Aiello A, Volfovsky A, Xu J
Biostatistics
. 2024 Aug;
26(1).
PMID: 39113272
We develop a stochastic epidemic model progressing over dynamic networks, where infection rates are heterogeneous and may vary with individual-level covariates. The joint dynamics are modeled as a continuous-time Markov...
9.
Elghawy O, Patel R, Xu J, Sussman J, Horton B, Kaur V
Cancer Invest
. 2024 May;
42(5):400-407.
PMID: 38773947
The CNS is a common site for distant metastasis and treatment failure in melanoma patients. This study aimed to evaluate the inclusion rate of patients with melanoma brain metastases (MBM)...
10.
Bandyopadhyay S, Duffy M, Ahn K, Sussman J, Pang M, Smith D, et al.
Cell
. 2024 May;
187(12):3120-3140.e29.
PMID: 38714197
Non-hematopoietic cells are essential contributors to hematopoiesis. However, heterogeneity and spatial organization of these cells in human bone marrow remain largely uncharacterized. We used single-cell RNA sequencing (scRNA-seq) to profile...